Looks like another Labour policy is gone as government proposes funding Keytruda

The government has gazzumped Labour by authorising Pharmac to part-fund Keytruda, and all without having to entertain Big Pharma in their offices like Labour did.

Melanoma patients are likely to get a second drug treatment option under a new proposal to provide state funding of Keytruda.

Pharmac, the Government’s drug funding agency, has today issued a consultation document proposing to pay for Keytruda from September 1.

This follows Pharmac’s earlier decision to fund Keytruda’ rival Opdivo from this Friday. Both are high-cost cancer drugs in a new class of immunotherapy medicines, called PD-1 inhibitors which are extending the lives of some advanced-melanoma patients who have no other treatment options.

Pharmac says in the consultation notice on its website that it has “now reached a commercially favourable provisional agreement” with the maker of Keytruda (pembrolizumab), Merck Sharp and Dohme, and is seeking feedback on the proposal, which also involves two other drugs.  

“The proposal to fund pembrolizumab would result in a second PD-1 inhibitor being funded for patients with advanced melanoma.

“We are not aware of any evidence to support the use of pembrolizumab after nivolumab [Opdivo] treatment failure, or vice versa, but the two agents may have different side effect profiles; therefore, they may be useful alternatives to each other in patients who experience early treatment-limiting toxicity.

“Under the proposal switching between the two funded PD-1 inhibitor treatments would be permitted within the first 12 weeks of starting funded treatment if the first treatment choice is not tolerated and the patient’s cancer did not progress while on their first treatment.”

Some patients have been paying up to $300,000 for two years’ treatment with Keytruda. Some, who had been facing imminent death, have been told they are in remission on Keytruda.

So, Pharmac have used a competitive product to play hardball against Merck. Good. This is why Pharmac are needed and should not be a plaything of politicians.

This is great news for sufferers of melanoma.

 

– NZ Herald


Do you want:

  • Ad-free access?
  • Access to our very popular daily crossword?
  • Access to Incite Politics magazine articles?
  • Access to Podcasts?
  • Access to Political Polls?

Our subscribers’ financial support is the reason why we have been able to offer our latest service; Audio blogs. 

Click Here  to support us and watch the number of services grow.

As much at home writing editorials as being the subject of them, Cam has won awards, including the Canon Media Award for his work on the Len Brown/Bevan Chuang story.  And when he’s not creating the news, he tends to be in it, with protagonists using the courts, media and social media to deliver financial as well as death threats.

They say that news is something that someone, somewhere, wants kept quiet.   Cam Slater doesn’t do quiet, and as a result he is a polarising, controversial but highly effective journalist that takes no prisoners.

He is fearless in his pursuit of a story.

Love him or loathe him.  But you can’t ignore him.

40%